PD-1 Inhibitor Plus Chemotherapy as Conversion Therapy in Unresectable Gastric Cancer (STARS-GC01): A Single-arm, Single-center, Prospective Clinical Study.
Latest Information Update: 12 Feb 2024
At a glance
- Drugs Camrelizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Paclitaxel (Primary)
- Indications Cancer metastases; Gastric cancer; Liver metastases
- Focus Therapeutic Use
- 04 Feb 2024 Status changed from recruiting to completed.
- 07 Jun 2022 Results (n=31) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 03 Aug 2021 Status changed from not yet recruiting to recruiting.